Bayer (FRA:BAYN) Given a €61.00 Price Target at Warburg Research
Bayer (FRA:BAYN) has been given a €61.00 ($70.93) target price by equities research analysts at Warburg Research in a research report issued to clients and investors on Friday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. Warburg Research’s target price indicates a potential downside of 19.69% from the stock’s previous close.
Several other equities analysts also recently weighed in on the company. Liberum Capital set a €90.00 ($104.65) target price on Bayer and gave the company a “buy” rating in a research report on Wednesday. Kepler Capital Markets set a €73.00 ($84.88) price target on Bayer and gave the stock a “neutral” rating in a research report on Thursday, January 9th. Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the stock a “buy” rating in a research note on Monday. Deutsche Bank set a €70.00 ($81.40) price objective on Bayer and gave the company a “neutral” rating in a research report on Thursday, October 31st. Finally, HSBC set a €63.00 ($73.26) price objective on Bayer and gave the company a “neutral” rating in a research note on Wednesday, November 27th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Bayer has an average rating of “Buy” and a consensus price target of €81.61 ($94.90).
Shares of BAYN stock opened at €75.96 ($88.33) on Friday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98). The firm has a fifty day moving average price of €72.63 and a 200-day moving average price of €66.82.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: What is a support level?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.